MX2009003299A - [2-(6-fluor-1h-indol-3-ilsulfanil)bencil]metilamina para el tratamiento de trastornos afectivos. - Google Patents

[2-(6-fluor-1h-indol-3-ilsulfanil)bencil]metilamina para el tratamiento de trastornos afectivos.

Info

Publication number
MX2009003299A
MX2009003299A MX2009003299A MX2009003299A MX2009003299A MX 2009003299 A MX2009003299 A MX 2009003299A MX 2009003299 A MX2009003299 A MX 2009003299A MX 2009003299 A MX2009003299 A MX 2009003299A MX 2009003299 A MX2009003299 A MX 2009003299A
Authority
MX
Mexico
Prior art keywords
ylsulfanyl
indol
benzyl
treatment
flouro
Prior art date
Application number
MX2009003299A
Other languages
English (en)
Inventor
Jan Kehler
Karsten Juhl
Neil Anderson
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2009003299A publication Critical patent/MX2009003299A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

[2-(6-fluor-1H-indol-3-ilsulfanil)bencil]metilamina y sus sales aceptables para uso farmacéutico, siempre que no sea la base libre en una forma no cristalina se proporcionan para el tratamiento de trastornos afectivos.
MX2009003299A 2006-09-28 2007-09-27 [2-(6-fluor-1h-indol-3-ilsulfanil)bencil]metilamina para el tratamiento de trastornos afectivos. MX2009003299A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82729206P 2006-09-28 2006-09-28
DKPA200601251 2006-09-28
US86240206P 2006-10-20 2006-10-20
DKPA200700432 2007-03-20
PCT/DK2007/000419 WO2008037258A1 (en) 2006-09-28 2007-09-27 [2-(6-flouro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders

Publications (1)

Publication Number Publication Date
MX2009003299A true MX2009003299A (es) 2009-04-09

Family

ID=38670916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003299A MX2009003299A (es) 2006-09-28 2007-09-27 [2-(6-fluor-1h-indol-3-ilsulfanil)bencil]metilamina para el tratamiento de trastornos afectivos.

Country Status (7)

Country Link
US (1) US8138220B2 (es)
EP (1) EP2074091B1 (es)
JP (1) JP5600253B2 (es)
AU (1) AU2007302449A1 (es)
CA (1) CA2664258A1 (es)
MX (1) MX2009003299A (es)
WO (1) WO2008037258A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
TW200938189A (en) * 2008-03-13 2009-09-16 Lundbeck & Co As H [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
WO2010094289A1 (en) * 2009-02-20 2010-08-26 Aarhus Universitet Allosteric binding compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2005061455A1 (en) * 2003-12-23 2005-07-07 H. Lundbeck A/S 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
JP2009538117A (ja) * 2006-03-22 2009-11-05 ハー・ルンドベック・アクチエゼルスカベット うつ病を処置するための化合物を同定する方法

Also Published As

Publication number Publication date
EP2074091B1 (en) 2015-01-07
WO2008037258A1 (en) 2008-04-03
JP5600253B2 (ja) 2014-10-01
EP2074091A1 (en) 2009-07-01
WO2008037258A8 (en) 2009-03-19
AU2007302449A1 (en) 2008-04-03
US8138220B2 (en) 2012-03-20
US20090326036A1 (en) 2009-12-31
JP2010504922A (ja) 2010-02-18
CA2664258A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
TW200607799A (en) Therapeutic compounds: pyridine as scaffold
TW200726462A (en) Benzamide derivatives and uses related thereto
TW200635913A (en) Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
TW200716628A (en) Novel compounds
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
IL201796A (en) Indole-3-Inglet or its pharmaceutical salts for use in the treatment of dermal lesion caused by papillomavirus
MX352516B (es) Compuestos terapeuticos.
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
ZA200901050B (en) Benzyl amines,a process for their production and their use as anti-inflammatory agents
WO2007109288A3 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
IL179924A0 (en) 2 - (1h-indolylsulfanyl) - aryl amine derivatives for use in the treatment of affective disorders, pain adhd and stress urinary incontinence
TW200732304A (en) Piperidine derivatives
MX2009003299A (es) [2-(6-fluor-1h-indol-3-ilsulfanil)bencil]metilamina para el tratamiento de trastornos afectivos.
EP1796665A4 (en) COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
PT1948224E (pt) Preparação industrial, e a sua utilização na terapêutica da hipertensão
EP1866303A4 (en) METHOD AND METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE CIS-2-HYDROXYMETHYL-4- (CYTOSIN-1-YL) -1,3-OXATHIOLAN OR PHARMACEUTICALALLY SALTS THEREOF
SI1714647T1 (sl) Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj
MX2007007183A (es) Aminas, combinacion de aminas y vanadio y sales de amina y vanadio para el tratamiento o prevencion de dislipidemia.
AR069625A1 (es) Base libre de palonosetron y procedimiento para su preparacion
MX2007007485A (es) Derivados de cromano y usos de los mismos en el tratamiento de trastornos del sistema nervioso central.
PL1776366T3 (pl) Immunomodulujące oksopirazolocynoliny jako inhibitory CD80
NO20091642L (no) [2-(6-fluor-1H-indol-3-ylsulfanyl)benzyl]metylamin for behandling av affektive lidelser

Legal Events

Date Code Title Description
FA Abandonment or withdrawal